IL6 and COVID-19: The use of dexamethasone (and later also tocilizumab) may have contributed to the improved outcome of the δ-phenotype, because it is associated with the highest white blood cell counts in our COVID-19 cohort and was previously shown to be characterized by the most elevated IL-6 and TNF levels in sepsis patients[4].